Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $27.16M
• Dividend Yield: N/A
• Average Volume (3M): 811.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -44.63%
• EPS Growth: 26.80%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 78,510,315
• 10 Day Avg. Volume: 673,161
• 30 Day Avg. Volume: 811,466
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 4.02
• Enterprise Value/Revenue: 26.20
• Enterprise Value/Gross Profit: 29.62
• Enterprise Value/Ebitda: -6.02
• 1Y Price Target: $2.50
• Price Target Upside: 614.29% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 39 Underperform
• Price Target: $0.50 ▲(42.86% Upside)

Clearside Biomedical's overall stock score is heavily impacted by its poor financial performance and negative corporate events. The bearish technical indicators and poor valuation metrics further contribute to the low score. The company's strategic uncertainties and risk of delisting present significant risks to investors.

Positive Factors

Positive Trial Results

The Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results, maintaining stable BCVA and CST from baseline to Week 36.

Strategic Alternatives

CLSD announced plans to explore a full range of strategic alternatives with an investment bank to advance its CLS-AX program and maximize shareholder value.

Negative Factors

Funding Challenges

CLSD is facing difficulties in securing funding or partnerships to advance its CLS-AX program into phase 3 development.

Operational Changes

All internal research and development programs will pause during this process of exploring strategic alternatives.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Clearside Biomedical generates revenue primarily through the commercialization of its products, notably Xipere, which is sold to healthcare providers and patients. The company also explores partnerships and collaborations with larger pharmaceutical companies, which may include licensing agreements or co-development deals that provide upfront payments, milestone payments upon achieving development goals, and royalties on sales. Additionally, Clearside may benefit from research grants or funding from government and non-profit organizations aimed at supporting innovative treatments in eye care.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical faces significant financial challenges, with declining revenues, persistent losses, and a negative equity position. These factors indicate severe financial instability and an inability to generate positive cash flows.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.17M	1.66M	8.23M	1.33M	29.57M	7.89M
Gross Profit	3.69M	1.51M	7.87M	1.12M	29.57M	7.89M
EBITDA	-18.12M	-24.35M	-23.06M	-29.46M	554.00K	-17.70M
Net Income	-27.71M	-34.35M	-32.48M	-32.95M	376.00K	-18.21M
Balance Sheet
Total Assets	15.33M	25.13M	34.02M	51.30M	42.90M	19.32M
Cash, Cash Equivalents and Short-Term Investments	9.38M	20.02M	28.92M	48.26M	30.44M	17.29M
Total Debt	533.00K	52.47M	43.00M	35.26M	675.00K	1.98M
Total Liabilities	64.07M	63.98M	49.93M	40.70M	4.93M	10.56M
Stockholders Equity	-48.73M	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow
Free Cash Flow	-22.22M	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
Operating Cash Flow	-21.73M	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
Investing Cash Flow	10.85M	-638.00K	-1.78M	-246.00K	0.00	-55.00K
Financing Cash Flow	2.02M	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.53, and below the 200-day MA of 0.82, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 34.57 is Neutral, neither overbought nor oversold. The STOCH value of 17.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.95B	-0.40	-41.62%	2.21%	22.29%	-1.85%
ADAG	47 Neutral	$103.69M	―	-63.24%	―	-87.65%	11.76%
IVVD	44 Neutral	$222.25M	―	-120.08%	―	1941.08%	48.93%
ADVM	41 Neutral	$73.86M	―	-222.28%	―	―	1.80%
CLSD	39 Underperform	$27.16M	―	91.63%	―	-44.63%	26.80%
INZY	37 Underperform		―		―	―	-17.06%
JSPR	35 Underperform	$44.21M	―	-146.87%	―	―	-17.96%

Clearside Biomedical Corporate Events

Clearside Biomedical Approves Reverse Stock Split Proposal

On August 28, 2025, Clearside Biomedical received a notice from Nasdaq regarding non-compliance with the Market Value of Listed Securities requirement, giving the company until February 24, 2026, to regain compliance or face potential delisting. Additionally, on August 29, 2025, the company held a special meeting where stockholders approved a proposal for a reverse stock split to address a previous non-compliance issue related to the minimum bid price requirement, aiming to maintain its listing on Nasdaq.

Clearside Biomedical Announces New Chairperson Appointment

On February 7, 2025, Clearside Biomedical was notified by Nasdaq about non-compliance with the minimum bid price requirement, risking delisting. The company plans to request a hearing to maintain its listing and has filed for a reverse stock split to regain compliance. Additionally, Anthony Gibney resigned as Chairperson on August 11, 2025, succeeded by Clay B. Thorp.

Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges

On July 17, 2025, Clearside Biomedical announced it is exploring strategic alternatives to enhance shareholder value, including the sale or license of assets, partnerships, or mergers. To conserve resources, all employees, including top executives, will transition to consulting roles, and internal R&D programs will be paused. The company has retained Piper Sandler to assist in this strategic evaluation process. This move comes amid challenging economic conditions and aims to advance Clearside’s proprietary suprachoroidal delivery platform and ophthalmology pipeline. The workforce reduction is expected to incur charges of approximately $3.4 million in the third quarter of 2025.